Researcher
Ann Gils
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 31 Aug 2019
Projects
1 - 10 of 18
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicalsFrom28 Aug 2017 → 31 Dec 2021Funding: FWO Strategic Basic Research Grant
- Immunogenicity of biological agents in inflammatory bowel disease and psoriasis: clinical relevance of early detection, characterization and prevention of anti-drug antibodies.From1 Oct 2016 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Implementation of infliximab dosage regimen stratification through generalization/validation of rapid concentration-determining assays and generation of population-based pharmacokinetic/pharmacodynamic modelsFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseasesFrom1 Sep 2014 → 7 May 2019Funding: BOF - Doctoral projects
- Development, validation and clinical application of assas in order to perform blood concentration measurements of biological.From1 Oct 2013 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- Translating therapeutic drug monitoring of biopharmaceuticals into individualised care of inflammatory bowel disease patients through pharmacometric modelling en farmaco-economic evaluation.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
- Development and validation of rapid assays to quantify infliximab trough levels and antibodies towards infliximab.From17 Sep 2012 → 31 Dec 2017Funding: IWT personal funding - strategic basic research grants
- Optimizing treatment of IBD patients with anti-TNFalpha biopharmaceuticals via pharmacokinetic monitoring of trough levels and calculating the cost-effectiveness of this trough level based therapy.From1 Jan 2012 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
Publications
31 - 40 of 229
- Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing(2018)
Authors: Bram Verstockt, Sumin Bian, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante
Pages: 731 - 739 - Optimising Biological Treatment for Patients with Immune-Mediated Inflammatory Diseases Exposure-Response Relation and Therapy-Related Effects(2018)
Authors: Iris Detrez, Ann Gils, Marc Ferrante
- Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab(2018)
Authors: Marc Ferrante, Gert Van Assche, Paul Rutgeerts, João Guedelha Sabino, Niels Vande Casteele, Ann Gils, Séverine Vermeire
Pages: 1276 - 1283.e1 - INFLIXIMAB AND VEDOLIZUMAB SHOW A DIFFERENT EFFECT ON CLOT FORMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS(2018)
Authors: Iris Detrez, Vera Ballet, Miet Peeters, Gert Van Assche, Séverine Vermeire, Marc Ferrante, Ann Gils
Pages: S362 - S363 - Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial(2018)
Authors: Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 818 - 826 - USTEKINUMAB INDUCES CLINICAL AND BIOLOGICAL REMISSION IN BIOLOGIC REFRACTORY CROHN'S DISEASE PATIENTS: A REAL WORLD BELGIAN COHORT STUDY(2018)
Authors: Claire Liefferinckx, Bram Verstockt, Ann Gils, Maja Noman, Catherine Van Kemseke, Macken Elisabeth, Martine De Vos, Wouter Van Moerkercke, Jean-Francois Rahier, Peter Bossuyt, et al.
Pages: S830 - S831 - USTEKINUMAB INDUCES LIMITED MUCOSAL HEALING AFTER 6 MONTHS IN A REAL-LIFE, PROSPECTIVE COHORT OF PATIENTS WITH REFRACTORY CROHN'S DISEASE(2018)
Authors: Bram Verstockt, Maja Noman, Isolde Aerden, Miet Peeters, Els Brouwers, Vera Ballet, Liesbeth Vandersmissen, Gert A Van Assche, Ann Gils, Séverine Vermeire, et al.
Pages: S836 - S836 - Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial(2018)
Authors: Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 818 - 826 - INFLIXIMAB EXPOSURE PREDICTS SUPERIOR ENDOSCOPIC OUTCOMES IN PATIENTS WITH ACTIVE CROHN'S DISEASE: PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS OF TAILORIX(2018)
Authors: Erwin Dreesen, Geert R D'Haens, Filip J Baert, Benjamin Pariente, Yoram Bouhnik, Christien Janneke Van der Woude, Jacques Moreau, David Laharie, Séverine Vermeire, Ann Gils
Pages: S821 - S821 - REACTIVE DOSE ESCALATION OF INFLIXIMAB IN PATIENTS WITH CROHN'S DISEASE IN TAILORIX LEADS TO IMPROVED OUTCOMES(2018)
Authors: Erwin Dreesen, David Laharie, Guy Lambrecht, Peter Bossuyt, Anthony Buisson, Jerome Filippi, Philippe Van Hootegem, Geert R D'Haens, Séverine Vermeire, Ann Gils
Pages: S823 - S824
Patents
1 - 3 of 3
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)